Independent Research set a €120.00 ($142.86) price target on Bayer (FRA:BAYN) in a research report sent to investors on Friday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.

BAYN has been the subject of several other reports. Nord/LB reaffirmed a neutral rating on shares of Bayer in a report on Wednesday, December 27th. DZ Bank reaffirmed a buy rating on shares of Bayer in a report on Monday, December 11th. Barclays set a €105.00 ($125.00) target price on Bayer and gave the company a sell rating in a report on Monday, November 6th. Citigroup set a €130.00 ($154.76) target price on Bayer and gave the company a buy rating in a report on Thursday, October 5th. Finally, Baader Bank set a €140.00 ($166.67) target price on Bayer and gave the company a buy rating in a report on Thursday, September 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of €122.33 ($145.63).

Bayer (FRA:BAYN) opened at €104.44 ($124.33) on Friday. The company has a market capitalization of $86,250.00 and a P/E ratio of 28.00. Bayer has a fifty-two week low of €99.69 ($118.68) and a fifty-two week high of €123.82 ($147.40).

ILLEGAL ACTIVITY NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/15/independent-research-analysts-give-bayer-bayn-a-120-00-price-target.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Stock Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related stocks with our FREE daily email newsletter.